Antimicrobial Drug Discovery and Resistance

EasyChair Preprint 15062

Abstract

The emergence of antimicrobial resistance (AMR) poses a significant threat to public health, complicating the treatment of infectious diseases and leading to increased morbidity and mortality rates. This review discusses the current state of antimicrobial drug discovery, highlighting innovative strategies and technologies employed to identify and develop new therapeutic agents. We explore the mechanisms of resistance that bacteria, fungi, and viruses have evolved, including target modification, efflux pump overexpression, and biofilm formation, which undermine the efficacy of existing drugs. Furthermore, we examine the role of natural products and synthetic biology in discovering novel antimicrobials. The integration of genomics and proteomics is also discussed as a means to elucidate resistance pathways and facilitate the design of more effective inhibitors (Hu et al., 2019). Addressing the challenges in drug development, including the high cost and regulatory hurdles, we emphasize the need for collaborative efforts between academia, industry, and government entities to foster innovation in this critical area. Ultimately, a multifaceted approach combining novel drug discovery with robust stewardship programs is essential to combat AMR and safeguard public health.

Keyphrases: BET, Bromodomain, Epigenetics, inhibitor, kinase

@booklet{EasyChair:15062,
  author    = {Kaledio Potter and Axel Egon and Abram Gracias},
  title     = {Antimicrobial Drug Discovery and Resistance},
  howpublished = {EasyChair Preprint 15062},
  year      = {EasyChair, 2024}}